Phase 1 Trial of CA-4948 Recruiting Non-Hodgkin’s Lymphoma Patients
News
A Phase 1 clinical trial is recruiting relapsed or refractory non-Hodgkin’s lymphoma patients to determine the safest and most effective dose of the oral therapy CA-4948. The trial is now treating patients ... Read more